CEO Partner and Chief Executive Officer of Generate Biomedicines
Michael Nally joined Flagship in 2021 and serves as CEO Partner and Chief Executive Officer of Generate Biomedicines. Mike is an accomplished pharmaceutical executive, with significant experience leading global organizations.
Prior to joining Flagship, Mike spent nearly 18 years at Merck, where he was most recently Executive Vice President and Chief Marketing Officer of its Human Health division. In this role, he led the company’s global marketing strategy, commercialization model, and long-term growth strategy across its product portfolio. Mike previously served as President of Merck’s Global Vaccines division where he and his team increased the reach and public health impact of its portfolio of pediatric, adolescent, and adult vaccines resulting in significant business growth. He also led Merck’s business in Sweden and the UK, and developed innovative, customer-centered approaches that improved business results and accelerated patient access to the company’s medicines and vaccines. Additionally, he held a variety of senior positions at Merck in commercial operations, business development, and investor relations.
Mike holds an M.B.A. from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a B.A. in Economics from Middlebury College.